Founded 2008 | ||
Novus Scientific is an innovator in the development and commercialization of resorbable synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden.
Novus Scientific was founded in 2008 by the medical device entrepreneur Thomas Engström upon the sale of his previous company Radi Medical Systems AB to the U.S company St. Jude Medical.
The hemostasis division of Radi Medical was responsible for the development of a resorbable polymer seal device used for femoral arterial closure culminating in a product called Femoseal. Other products developed for market by Radi Medical Systems were the Pressurewire and modality known as Fractional Flow Reserve (FFR), FemoStop and RadiStop.
Having initiated R&D and filed the first patent back in 2004, Novus has developed the world's first long-term resorbable synthetic surgical mesh which was cleared for use by the FDA in February 2010 for use in reinforcement of soft tissue where weakness exists. Surgical procedures have been performed in the Far East and Europe as well as in the United States.
TIGR® Matrix Surgical Mesh
TIGR® Matrix Surgical Mesh is a 100 percent resorbable (100% absorbable), synthetic mesh, knitted from two different resorbable fibers that degrade at different rates following the placement of the mesh. Fiber 1 is strong for 1 – 2 weeks and is completely gone in 4 months. Fiber 2 is strong for 6 – 9 months and is completely gone in 3 years. TIGR® Matrix was developed based on the hypothesis that soft tissue positively remodels in response to the stimulus of increased mechanical load – a process known as "mechanotransduction", which is the physiological process by which cells sense and respond to mechanical loads. This key feature contributes to the functional regenerated tissue that ultimately replaces the degraded mesh, as shown in preclinical trials. This allows the body to heal effectively, ideally, forming strong tissue as the mesh is absorbed.